- Conditions
- Idiopathic Parkinson's Disease, Parkinson Disease, Depression
- Interventions
- Transcranial Direct Current Stimulation
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 80
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Idiopathic Parkinson's Disease
- Interventions
- Rotigotine, Placebo
- Drug
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Rotigotine
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 31 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more
- Conditions
- Idiopathic Parkinson's Disease (PD)
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 79 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parkinson Disease
- Interventions
- CVN424 75 mg, CVN424 150 mg, Placebo
- Drug
- Lead sponsor
- Cerevance
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- tozadenant, placebo
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Loma Linda, California + 37 more
- Conditions
- Parkinson's Disease
- Interventions
- NR2B NMDA Antagonist CP-101,606 (traxoprodil)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Early-Stage Parkinson's Disease
- Interventions
- Rotigotine
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 31 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,667 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301 Low Dose, CVT-301 High Dose, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
- Conditions
- Parkinson's Disease With Cognitive Impairments
- Interventions
- safinamide, placebo
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 9
- States / cities
- Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Parkinson Disease, Idiopathic Parkinson Disease
- Interventions
- [F-18] Fluorodopa Positron Emission Tomography, OM Meditation
- Drug · Behavioral
- Lead sponsor
- Andrew Newberg
- Other
- Eligibility
- 25 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Istradefylline 40 mg, Istradefylline 20 mg, Placebo
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
- Conditions
- Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
- Interventions
- NEU-411, Placebo
- Drug · Other
- Lead sponsor
- Neuron23 Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 45
- States / cities
- Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
- Conditions
- Orthostatic Hypotension, Idiopathic Parkinson Disease
- Interventions
- Droxidopa 100 MG [Northera]
- Drug
- Lead sponsor
- Alberto Espay, MD, MSc
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Parkinson Disease
- Interventions
- Blood draw
- Other
- Lead sponsor
- Molecular Biometrics, Inc.
- Industry
- Eligibility
- 46 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, IPX054 300 mg
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Sunnyvale, California • Lawrence, Kansas
- Conditions
- Parkinson's Disease
- Interventions
- Mesenchymal Stem Cells, Placebo
- Drug
- Lead sponsor
- Mya Schiess
- Other
- Eligibility
- 50 Years to 79 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parkinson's Disease
- Interventions
- ExAblate Transcranial System
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Movement Disorders, Neurology, Parkinsons Disease
- Interventions
- Exablate Pallidotomy, Unilateral
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 30 Years to 99 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Parkinson Disease, Idiopathic Parkinson Disease
- Interventions
- N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
- Dietary Supplement · Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Safinimide 50-100 mg/day, Matching Placebo
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Parkinson Disease
- Interventions
- NeuraLight
- Other
- Lead sponsor
- NeuraLight
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Lee Silverman Voice Treatment, SpeechVive, Control
- Behavioral · Device
- Lead sponsor
- University of Massachusetts, Amherst
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- West Lafayette, Indiana • Amherst, Massachusetts